Contact us
Innovation
Company
Therapeutic areas
Investors
News
Career
Contact
Verigraft
Arvid Wallgrens Backe 20
41346 Gothenburg
Sweden
info@verigraft.com
Home
/
News
/
VERIGRAFT reports promising interim…
News
Published: October 9, 2023
VERIGRAFT reports promising interim results from a first-in-man study in patients with deep venous insufficiency at 2023 Cell & Gene Meeting on the Mesa
Link to the article
Latest news
See all news
Published: May 13, 2026
VERIGRAFT Receives CTA Approval for Phase II/III Study of P-TEV
Published: May 7, 2026
VERIGRAFT Q1 2026 – Continued Clinical Progress
Published: April 20, 2026
VERIGRAFT Selected as Finalist in Health Tech Award 2026
Published: March 2, 2026
VERIGRAFT expands its network within advanced therapy applications through EU-funded Doctoral Network VISI-ON-BRAIN
Uncategorized
Published: February 12, 2026
VERIGRAFT announces a committed capital contribution of SEK 110 million to advance pivotal trial program in Europe and the US
Uncategorized
Published: February 10, 2026
Technology collaboration with South Korea